Houston startup upgrades tech to better serve moms at home during COVID-19

HOUSTON INNOVATORS PODCAST EPISODE 29

Amanda Ducach quickly upgraded her app, SocialMama, to help increase virtual access to health care professionals for moms stuck inside during the COVID-19 crisis. Photo courtesy of SocialMama

With much of society working from home, a huge burden has been placed on parents who are juggling their careers and homeschooling their children for the rest of the academic year. In many situations, the bulk of this responsibility has weighed heavy on moms, and a Houston momtrepreneur knew how to help them out.

Amanda Ducach, founder and CEO of SocialMama, created her app to link up moms for friendship and mentorship, and she was planning on expanding the app to add in experts and professionals into the mix this summer. However, when COVID-19 hit, she realized this was something moms needed ASAP.

"We learned quickly that moms' behaviors were drastically changing throughout this process of the pandemic, but also that over a million babies were going to be born in isolation," Ducach says on this week's episode of the Houston Innovators Podcast. "That really changes the walk around maternal health."

The experts that are now on the app include mental health professionals, OBGYN doctors, and more. They are able to interface with users in a casual way to weigh in on topics of concern with their expertise. While Ducach and her team worked quickly to get the first version of the new feature online, she says she is working on technological improvements. However, she has already received great feedback from users and the experts.

While working in isolation and caring for her family at the same time, Ducach has been adjusting to this new normal just as everyone else. She said on the podcast that she hopes a lesson companies learn from this experience is how work-life balance and productivity aren't mutually exclusive — and that they bring this realization into the future.

"A lot of the times we don't do a good job as a society understanding that moms are just as good of workers in a company as non-moms, but they need some level of flexibility. It's just the reality," Ducach says. "You can't be a parent and never leave at 3 o'clock to go bring your kid to a baseball game. We have to support parents who work."

Ducach shares more of her growth plans in store for SocialMama, fundraising in the time of COVID-19 and federal relief woes, and more on the podcast episode. Listen to the full episode below — or wherever you get your podcasts — and subscribe for weekly episodes.


Hospital systems and nonprofits are looking for ways to reach patients virtually as face-to-face interactions continue to be limited due to the coronavirus. Getty Images

Houston medical organizations pivot to telemedicine and remote care amid COVID-19 crisis

online care

Hospitals across the country are trying their best to limit the number of people coming in and out — but how does that affect patients in need of non-COVID-19 treatment? Hospital systems are implementing new technology and training so that physicians can use telemedicine to connect virtually.

In March following telemedicine training, Houston Methodist began seeing hundreds more daily telemedicine sessions across its system, Josh Sol, administrative director of Innovation and Ambulatory Clinical Systems at Houston Methodist, previously told InnovationMap. And other hospital systems are following suit.

HCA Houston Healthcare's CareNow locations have implemented Virtual Care, a telehealth urgent care service. Patients can check in online during the urgent care center's operating hours to gain one-on-one access to care from a CareNow physician, nurse practitioner, or physician assistant. Providers, via video chat, will evaluate minor conditions and can prescribe non-narcotic medications when indicated.

If the situation calls for it, providers will tell the patient to come onsite to continue care.

"Virtual Care is an extension of our clinical urgent care services and fully supports our purpose to help people return to what they value in their lives, in an even more convenient way. We are proud to provide an easy solution for our patients' healthcare needs at their fingertips," says Dr. Mujtaba Ali-Khan, chief medical officer for HCA Houston Healthcare, in a news release.

Dallas-based CareNow was acquired by HCA in 2015 and has 16 locations in the greater Houston area.

Health care nonprofits are also taking advantage of remote ways to reach patients. Houston-based nonprofit CanCare is in the business of supporting cancer patients and their families and, despite a global pandemic, has not let up on its services to those in need. In fact, cancer patients with their weakened immune system are at greater risk of developing COVID-19 and are in need more than ever of CanCare's one-on-one matching emotional support service.

"The cancer community is in our thoughts and prayers during this time of uncertainty," says CanCare's President and CEO Cristina Vetrano in a news release. "Now more than ever, the community needs the help of our volunteers and support services. Our mission is not only to ensure the safety of clients, patients and caregivers but also to assure the community that they will continue to receive support throughout this challenging time."

Cancer patients can reach support via email at support@cancare.org or by calling the support line support line at 713-364-1652.

The Houston health care ecosystem will continue to see advances in telemedicine and remote care. One Houston startup, Medical Informatics, has created a virtual ICU program, called Sickbay, and the tech tool is being used to remotely monitor patients in Houston Methodist. The program works around the clock from a control hub to use artificial intelligence and algorithms to monitor patients.

"We designed our Sickbay platform to give lost data back to doctors, nurses and other members of the care team so they could save more lives," says Vincent Gagne, vice president of product for MIC, in a news release.

As the world emerges from COVID-19 — whenever and however that happens — telemedicine will have advanced as a viable option for physicians in a quicker way than it would have otherwise, Sol says.

"Telemedicine is here to stay now with the rapid adoption that just happened," he says. "The landscape will change tremendously."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings